{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:57:47Z","timestamp":1791309467790,"version":"4.3.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>Epithelial-myoepithelial carcinoma (EMC) is a rare salivary gland cancer characterized by biphasic tubular structures composed of inner ductal and outer clear myoepithelial cells. Because of its histologic variety and overlap of histologic features with other salivary gland tumors, there are broad differential diagnoses. The <jats:italic toggle=\"yes\">HRAS<\/jats:italic> Q61R mutation has been reported to be frequent in and specific to EMC. We evaluated the usefulness of RAS Q61R mutant-specific immunohistochemical (IHC) staining for detecting this genetic alteration in EMC. We investigated 83 EMC cases and 66 cases of salivary gland tumors with an EMC-like component, including pleomorphic adenoma, adenoid cystic carcinoma, basal cell adenoma\/adenocarcinoma, and myoepithelial carcinoma. Sanger sequencing was performed for <jats:italic toggle=\"yes\">HRAS<\/jats:italic>, <jats:italic toggle=\"yes\">KRAS<\/jats:italic>, and <jats:italic toggle=\"yes\">NRAS<\/jats:italic>. The diffuse and membranous\/cytoplasmic RAS Q61R IHC expression was observed in 65% of EMC cases, in which all cases harbored the <jats:italic toggle=\"yes\">HRAS<\/jats:italic> Q61R mutation. IHC-positive cases were present only in <jats:italic toggle=\"yes\">de novo<\/jats:italic> EMCs (54\/76 cases, 71%) but not in EMCs ex pleomorphic adenoma. The immunoreactivity was almost always restricted to the myoepithelial cells. Conversely, all EMC cases lacking the <jats:italic toggle=\"yes\">HRAS<\/jats:italic> Q61R mutation were negative on IHC. In addition, only 3% of EMC-like tumors showed the abovementioned immunopositivity. None of the cases examined carried <jats:italic toggle=\"yes\">KRAS<\/jats:italic> or <jats:italic toggle=\"yes\">NRAS<\/jats:italic> mutations. IHC for RAS Q61R is highly sensitive and specific for detecting the <jats:italic toggle=\"yes\">HRAS<\/jats:italic> Q61R mutation in EMC. Since significant immunopositivity was almost exclusively identified in nearly two thirds of EMCs but seldom in the histologic mimics, the IHC of RAS Q61R is a useful tool for diagnosing EMC in general pathology laboratories.<\/jats:p>","DOI":"10.1097\/pas.0000000000001673","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T01:55:57Z","timestamp":1611280557000},"page":"885-894","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":44,"title":["The Diagnostic Utility of RAS Q61R Mutation-specific Immunohistochemistry in Epithelial-Myoepithelial Carcinoma"],"prefix":"10.1097","volume":"45","author":[{"given":"Masato","family":"Nakaguro","sequence":"first","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA"},{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Tanigawa","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Hirai","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinari","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Urano","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Fujita Health University, School of Medicine, Toyoake, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisuke H.","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoi","family":"Sukeda","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Okumura","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Honda","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Tasaki","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoaki","family":"Tsukahara","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Matsubayashi","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Faquin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Sadow","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Nagao","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/PAS.0000000000001258","article-title":"Diagnostic significance of HRAS mutations in epithelial-myoepithelial carcinomas exhibiting a broad histopathologic spectrum","volume":"43","author":"Urano","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/01.pas.0000213314.74423.d8","article-title":"Epithelial-myoepithelial carcinoma: a review of the clinicopathologic spectrum and immunophenotypic characteristics in 61 tumors of the salivary glands and upper aerodigestive tract","volume":"31","author":"Seethala","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/PAS.0b013e318160852a","article-title":"Sebaceous epithelial-myoepithelial carcinoma of the salivary gland: clinicopathologic and immunohistochemical analysis of 6 cases of a new histologic variant","volume":"32","author":"Shinozaki","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"950","DOI":"10.5858\/133.6.950","article-title":"New variants of epithelial-myoepithelial carcinoma: oncocytic-sebaceous and apocrine","volume":"133","author":"Seethala","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12105-012-0350-y","article-title":"A double-clear variant of epithelial-myoepithelial carcinoma of the parotid gland","volume":"6","author":"Hussaini","year":"2012","journal-title":"Head Neck Pathol"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12105-013-0506-4","article-title":"HRAS mutations in epithelial-myoepithelial carcinoma","volume":"8","author":"Chiosea","year":"2014","journal-title":"Head Neck Pathol"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/PAS.0000000000000933","article-title":"Epithelial-myoepithelial carcinoma: frequent morphologic and molecular evidence of preexisting pleomorphic adenoma, common HRAS mutations in PLAG1-intact and HMGA2-intact cases, and occasional TP53, FBXW7, and SMARCB1 alterations in high-grade cases","volume":"42","author":"El Hallani","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41568-018-0076-6","article-title":"A model for RAS mutation patterns in cancers: finding the sweet spot","volume":"18","author":"Li","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00401-009-0595-z","article-title":"Monoclonal antibody specific for IDH1 R132H mutation","volume":"118","author":"Capper","year":"2009","journal-title":"Acta Neuropathol"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","article-title":"Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody","volume":"122","author":"Capper","year":"2011","journal-title":"Acta Neuropathol"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/modpathol.2014.137","article-title":"Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma","volume":"28","author":"Massi","year":"2015","journal-title":"Mod Pathol"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ajcp\/aqv015","article-title":"Immunohistochemical detection of NRASQ61R mutation in diverse tumor types","volume":"145","author":"Dias-Santagata","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/PAI.0000000000000500","article-title":"SP174 antibody lacks specificity for NRAS Q61R and cross-reacts with HRAS and KRAS Q61R mutant proteins in malignant melanoma","volume":"26","author":"Felisiak-Gol\u0105bek","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"564","DOI":"10.5858\/arpa.2016-0147-OA","article-title":"SP174, NRAS Q61R mutant-specific antibody, cross-reacts with KRAS Q61R mutant protein in colorectal carcinoma","volume":"141","author":"Lasota","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/his.14057","article-title":"Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas","volume":"76","author":"Pareja","year":"2020","journal-title":"Histopathology"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/PAS.0000000000000740","article-title":"NRASQ61R mutation-specific immunohistochemistry also identifies the HRASQ61R mutation in medullary thyroid cancer and may have a role in triaging genetic testing for MEN2","volume":"41","author":"Reagh","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12105-020-01140-4","article-title":"Salivary gland cancer in the era of routine next-generation sequencing","volume":"14","author":"Todorovic","year":"2020","journal-title":"Head Neck Pathol"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1097\/PAS.0000000000000980","article-title":"The role of molecular testing in the differential diagnosis of salivary gland carcinomas","volume":"42","author":"Sk\u00e1lov\u00e1","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/PAS.0000000000000669","article-title":"Distinctive patterns of CTNNB1 (\u03b2-catenin) alterations in salivary gland basal cell adenoma and basal cell adenocarcinoma","volume":"40","author":"Jo","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.prp.2017.12.016","article-title":"Wnt\/\u03b2-catenin signal alteration and its diagnostic utility in basal cell adenoma and histologically similar tumors of the salivary gland","volume":"214","author":"Sato","year":"2018","journal-title":"Pathol Res Pract"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/his.13990","article-title":"Histopathological evaluation of minor salivary gland papillary-cystic tumours: focus on genetic alterations in sialadenoma papilliferum and intraductal papillary mucinous neoplasm","volume":"76","author":"Nakaguro","year":"2020","journal-title":"Histopathology"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12105-019-01068-4","article-title":"Salivary sialadenoma papilliferum consists of two morphologically, immunophenotypically, and genetically distinct subtypes","volume":"14","author":"Hsieh","year":"2020","journal-title":"Head Neck Pathol"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/modpathol.2011.86","article-title":"Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms","volume":"24","author":"Brill","year":"2011","journal-title":"Mod Pathol"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/his.13845","article-title":"Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma","volume":"75","author":"Hung","year":"2019","journal-title":"Histopathology"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/his.13341","article-title":"PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with PLAG1 genetic abnormalities","volume":"72","author":"Katabi","year":"2018","journal-title":"Histopathology"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/his.13246","article-title":"HMGA2 is a specific immunohistochemical marker for pleomorphic adenoma and carcinoma ex-pleomorphic adenoma","volume":"71","author":"Mito","year":"2017","journal-title":"Histopathology"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"59023","DOI":"10.18632\/oncotarget.19812","article-title":"Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification","volume":"8","author":"Takase","year":"2017","journal-title":"Oncotarget"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.18632\/oncotarget.22927","article-title":"Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas","volume":"9","author":"Shimura","year":"2018","journal-title":"Oncotarget"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000447622","article-title":"PLAG1: an immunohistochemical marker with limited utility in separating pleomorphic adenoma from other basaloid salivary gland tumors","volume":"60","author":"Avadhani","year":"2016","journal-title":"Acta Cytol"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12022-016-9466-z","article-title":"Detecting N-RAS Q61R mutated thyroid neoplasias by immunohistochemistry","volume":"28","author":"Crescenzi","year":"2017","journal-title":"Endocr Pathol"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/PAI.0000000000000333","article-title":"NRASQ61R mutation-specific immunohistochemistry is highly specific for either NRASQ61R or KRASQ61R mutation in colorectal carcinoma","volume":"25","author":"Turchini","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R34-20250608","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pathol.2017.01.008","article-title":"NRASQ61R immunohistochemistry detects both NRASQ61R and KRASQ61R mutations in colorectal cancer","volume":"49","author":"Jhuang","year":"2017","journal-title":"Pathology"},{"key":"R35-20250608","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jaad.2015.01.012","article-title":"Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma","volume":"72","author":"Ilie","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R36-20250608","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1146\/annurev.immunol.24.021605.090723","article-title":"Compartmentalized Ras\/MAPK signaling","volume":"24","author":"Mor","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"R37-20250608","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1038\/modpathol.2016.190","article-title":"Basaloid\/blue salivary gland tumors","volume":"30","author":"Seethala","year":"2017","journal-title":"Mod Pathol"},{"key":"R38-20250608","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/PAS.0b013e3181e366d2","article-title":"Epithelial-myoepithelial carcinoma with high grade transformation","volume":"34","author":"Roy","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"suppl 1","key":"R39-20250608","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1007\/s12105-013-0458-8","article-title":"\u201cDedifferentiation\u201d and high-grade transformation in salivary gland carcinomas","volume":"7","author":"Nagao","year":"2013","journal-title":"Head Neck Pathol"},{"key":"R40-20250608","first-page":"243","article-title":"Cytologic and histologic aspects of high-grade transformation of salivary gland carcinoma","volume":"25","author":"Nakaguro","year":"2020","journal-title":"AJSP Rev Rep"},{"key":"R41-20250608","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s004280050344","article-title":"High-grade carcinoma component in epithelial-myoepithelial carcinoma of salivary glands clinicopathological, immunohistochemical and flow-cytometric study of three cases","volume":"434","author":"Alos","year":"1999","journal-title":"Virchows Arch"},{"key":"R42-20250608","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jasc.2020.06.004","article-title":"Navigating small biopsies of salivary gland tumors: a pattern-based approach","volume":"9","author":"Nix","year":"2020","journal-title":"J Am Soc Cytopathol"},{"key":"R43-20250608","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cncy.22288","article-title":"Salivary duct carcinoma: updates in histology, cytology, molecular biology, and treatment","volume":"128","author":"Nakaguro","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"R44-20250608","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/PAS.0000000000001275","article-title":"Adenomyoepitheliomas of the breast frequently harbor recurrent hotspot mutations in PIK3-AKT Pathway-related genes and a subset show genetic similarity to salivary gland epithelial-myoepithelial carcinoma","volume":"43","author":"Lubin","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R45-20250608","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41467-018-04128-5","article-title":"Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas","volume":"9","author":"Geyer","year":"2018","journal-title":"Nat Commun"},{"key":"R46-20250608","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12901-018-0063-2","article-title":"Epithelial-myoepithelial carcinoma: a population-based survival analysis","volume":"18","author":"Gore","year":"2018","journal-title":"BMC Ear Nose Throat Disord"},{"key":"R47-20250608","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/0194599815594788","article-title":"Epithelial-myoepithelial carcinoma of the salivary glands: an analysis of 246 cases","volume":"153","author":"V\u00e1zquez","year":"2015","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R48-20250608","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"R49-20250608","doi-asserted-by":"crossref","first-page":"42183","DOI":"10.18632\/oncotarget.5619","article-title":"Mutant HRAS as novel target for MEK and mTOR inhibitors","volume":"6","author":"Kiessling","year":"2015","journal-title":"Oncotarget"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T22:03:14Z","timestamp":1749420194000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001673","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,19]]}}}